AUS
NZ
UK
CA
USA
IND
Highlight:
- Striate+ enters Germany, Austria, and Switzerland following strong EU and UK traction
- Distribution partner BioHorizons Camlog initiates first sales in the DACH region
- Clinical success and surgeon feedback underpin rapid global expansion strategy
Orthocell Ltd (ASX:OCC) has expanded the distribution of its flagship dental regenerative product, Striate+™, into Germany, Austria, and Switzerland—collectively known as the DACH region. This marks a significant milestone in the company’s European growth trajectory, following established momentum in both the European Union and the United Kingdom. The new market entry is supported by BioHorizons Camlog, a subsidiary of BioHorizons, which manages Striate+ marketing and distribution activities across Europe.
BioHorizons Camlog is a recognised distributor in the dental sector, with a strong presence in the high-growth DACH region. Following a period of targeted pre-launch activities, the group has now completed preparations and placed the first commercial orders for Striate+. This development sets the stage for revenue expansion in a market that plays a crucial role in global dental care and innovation. Orthocell is targeting a 20% market share within a global dental bone regeneration market estimated to exceed A$1 billion.
The acceleration into the DACH market builds on Orthocell’s success across current territories, supported by growing demand and positive clinical outcomes. Feedback from dental professionals continues to be highly encouraging, reinforced by data from a post-market clinical study showing a 98.6% success rate for Striate+ in dental implant procedures. This performance has significantly boosted surgeon confidence and contributed to strong commercial traction in key geographies.
Striate+ is a resorbable, sterile collagen membrane used in guided bone and tissue regeneration procedures within dental applications. The product plays a critical role in promoting osteogenesis by protecting bone defects from soft tissue intrusion, thereby ensuring the formation of stable, high-quality bone. Its clinical profile and ease of use have made it a preferred solution among dental surgeons engaged in implant-based treatments.
Orthocell’s broader strategy involves working closely with BioHorizons to extend its market reach into other high-potential territories. The company is particularly focused on entering the Brazilian market, where regulatory approval is anticipated within the next three months. Brazil represents a significant commercial opportunity due to the scale and growth rate of the region's dental sector.
Financially, Orthocell remains well-positioned to support its commercial growth objectives. The company holds approximately $32 million in cash, providing a solid foundation for scaling its operations, investing in market expansion, and supporting product uptake across multiple geographies. This capital strength enables Orthocell to maintain its momentum in both existing and newly targeted markets.
The latest market entry into Germany, Austria, and Switzerland follows a deliberate and strategic approach, leveraging established distributor networks and surgeon advocacy to optimise market penetration. With BioHorizons Camlog’s footprint and commercial capabilities, Orthocell is expected to benefit from accelerated brand exposure and increased sales conversion in the region.
Beyond commercial distribution, Orthocell continues to prioritise clinical excellence and product performance validation. The impressive results of the Striate+ clinical study, combined with consistent feedback from practitioners, have played a crucial role in driving product demand. These outcomes align with a global shift toward regenerative dentistry solutions that offer predictable, safe, and effective outcomes.
The company’s forward strategy is grounded in strengthening its presence in key global markets while building a sustainable revenue model through premium, clinically validated products. Striate+ has emerged as a cornerstone of this strategy, offering proven value in a competitive market and serving as a launchpad for broader portfolio expansion.
The integration of scientific rigor, commercial execution, and strategic distribution partnerships continues to define Orthocell’s approach to international market penetration. With expansion into the DACH region now underway and further territories on the horizon, Orthocell remains focused on scaling its impact in the global regenerative medicine landscape.
